(BIM) Biomerieux - PA
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: PA (France) | Market Cap: 8.139m EUR | Total Return: -42.7% in 12m
Avg Turnover: 12.9M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
bioMérieux S.A. is a France-based company that develops, manufactures, and markets in vitro diagnostic (IVD) solutions, with a primary focus on infectious diseases. It sells its products worldwide and operates through two segments: Clinical Applications (serving medical and clinical laboratories) and Industrial Applications (serving food, pharmaceutical, and other industrial customers with microbiological quality-control testing). The company was founded in 1963, is headquartered in Marcy-lÉtoile, France, and operates as a subsidiary of Institut Mérieux SA.
Its product portfolio spans the full microbiology workflow, including chromogen culture media (CHROMID), automated blood culture systems (BACT/ALERT VIRTUO), multiplex and point-of-care PCR platforms (BIOFIRE and BIOFIRE SPOTFIRE), mass spectrometry identification (VITEK MS), automated and rapid antimicrobial susceptibility testing (VITEK 2, VITEK REVEAL, ETEST), and the VIDAS immunoassay line for markers such as sepsis. It also offers whole-genome sequencing tools (BIOMERIEUX EPISEQ CS), sample-preparation systems (EMAG, NUCLISENS), industrial pathogen detection kits (GENE-UP, VERIFLOW), and a software suite (Biomérieux Vision Suite) to support diagnostic and clinical decision-making.
BioMérieux sits within the global IVD industry, where the typical business model combines recurring reagent and consumable sales with installed-base instrument placements. The dual Clinical/Industrial structure is a distinguishing feature, as the industrial microbiology segment supplies quality-control testing to food, beverage, and cosmetics manufacturers, providing some diversification away from the more cyclical clinical diagnostics market.
- BIOFIRE multiplex PCR panel sales accelerate clinical segment growth
- Food safety regulation lifts industrial microbiology demand
- Dollar weakness pressures reported revenue from North American sales
| Net Income: 681.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 10.40 > 1.0 |
| NWC/Revenue: 21.29% < 20% (prev 34.33%; Δ -13.04% < -1%) |
| CFO/TA 0.26 > 3% & CFO 1.46b > Net Income 681.4m |
| Net Debt (300.1m) to EBITDA (1.60b): 0.19 < 3 |
| Current Ratio: 2.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (119.0m) vs 12m ago 0.02% < -2% |
| Gross Margin: 53.06% > 18% (prev 55.66%; Δ -2.60% > 0.5%) |
| Asset Turnover: 122.2% > 50% (prev 68.98%; Δ 53.24% > 0%) |
| Interest Coverage Ratio: 30.40 > 6 (EBIT TTM 940.9m / Interest Expense TTM 30.9m) |
| A: 0.26 (Total Current Assets 2.54b - Total Current Liabilities 1.06b) / Total Assets 5.57b |
| B: 0.07 (Retained Earnings 397.5m / Total Assets 5.57b) |
| C: 0.17 (EBIT TTM 940.9m / Avg Total Assets 5.67b) |
| D: 2.79 (Book Value of Equity 4.10b / Total Liabilities 1.47b) |
| Altman-Z'' = 6.02 = AAA |
| DSRI: 0.68 (Receivables 1.01b/857.6m, Revenue 6.93b/3.98b) |
| GMI: 1.05 (GM 55.66% / 53.06%) |
| AQI: 0.91 (AQ_t 0.25 / AQ_t-1 0.27) |
| SGI: 1.74 (Revenue 6.93b / 3.98b) |
| TATA: -0.14 (NI 681.4m - CFO 1.46b) / TA 5.57b) |
| Beneish M = -2.79 (Cap -4..+1) = A |
As of June 25, 2026, the stock is trading at EUR 68.15 with a total of 163,403 shares traded. Over the past week, the price has changed by +0.59%, over one month by -6.70%, over three months by -23.37% and over the past year by -42.67%.
Current recommended Stop Loss: 65.80 (which is 3.4% or 1.3 ATR below the current price).
Biomerieux has no consensus analysts rating.
P/E Trailing = 20.6587
P/E Forward = 16.6945
P/S = 1.9998
P/B = 1.9841
P/EG = 1.2686
Revenue TTM = 6.93b EUR
EBIT TTM = 940.9m EUR
EBITDA TTM = 1.60b EUR
Long Term Debt = 211.3m EUR (from longTermDebt, last quarter)
Short Term Debt = 131.4m EUR (from shortTermDebt, last quarter)
Debt = 612.2m EUR (from shortLongTermDebtTotal, last quarter) + Leases 150.8m
Net Debt = 300.1m EUR (calculated: Debt 612.2m - CCE 312.1m)
Enterprise Value = 8.44b EUR (8.14b + Debt 612.2m - CCE 312.1m)
Interest Coverage Ratio = 30.40 (Ebit TTM 940.9m / Interest Expense TTM 30.9m)
EV/FCF = 10.90x (Enterprise Value 8.44b / FCF TTM 774.5m)
FCF Yield = 9.18% (FCF TTM 774.5m / Enterprise Value 8.44b)
FCF Margin = 11.17% (FCF TTM 774.5m / Revenue TTM 6.93b)
Net Margin = 9.83% (Net Income TTM 681.4m / Revenue TTM 6.93b)
Gross Margin = 53.06% ((Revenue TTM 6.93b - Cost of Revenue TTM 3.25b) / Revenue TTM)
Gross Margin QoQ = 49.00% (prev 57.09%)
Tobins Q-Ratio = 1.51 (Enterprise Value 8.44b / Total Assets 5.57b)
Interest Expense / Debt = 5.06% (Interest Expense 30.9m / Debt 612.2m)
Taxrate = 26.57% (243.9m / 918.0m)
NOPAT = 690.9m (EBIT 940.9m * (1 - 26.57%))
Current Ratio = 2.39 (Total Current Assets 2.54b / Total Current Liabilities 1.06b)
Debt / Equity = 0.15 (Debt 612.2m / totalStockholderEquity, last quarter 4.10b)
Debt / EBITDA = 0.19 (Net Debt 300.1m / EBITDA 1.60b)
Debt / FCF = 0.39 (Net Debt 300.1m / FCF TTM 774.5m)
Total Stockholder Equity = 4.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.01% (Net Income 681.4m / Total Assets 5.57b)
RoE = 16.92% (Net Income TTM 681.4m / Total Stockholder Equity 4.03b)
RoCE = 22.20% (EBIT 940.9m / Capital Employed (Equity 4.03b + L.T.Debt 211.3m))
RoIC = 15.96% (NOPAT 690.9m / Invested Capital 4.33b)
WACC = 6.21% (E(8.14b)/V(8.75b) * Re(6.40%) + D(612.2m)/V(8.75b) * Rd(5.06%) * (1-Tc(0.27)))
Discount Rate = 6.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 22.47 | Cagr: 0.03%
[DCF] Terminal Value 77.97% ; FCFF base≈545.2m ; Y1≈625.0m ; Y5≈919.8m
[DCF] Fair Price = 114.8 (EV 13.8b - Net Debt 300.1m = Equity 13.5b / Shares 118.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: -23.13 | Revenue CAGR: -3.97% | SUE: -0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=4.41 | Chg30d=-1.72% | Revisions=-20% | GrowthEPS=-4.9% | GrowthRev=+1.1%
EPS next Year (2027-12-31): EPS=4.92 | Chg30d=-1.31% | Revisions=-20% | GrowthEPS=+11.5% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: -20%